Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Current Oncology (Toronto, Ont.)|June 25, 2026
Real-World Survival Outcomes Following Chemoradiotherapy with or Without Durvalumab in PD-L1-Defined Subgroups of Stage III Unresectable NSCLCJanne Selke, Yvonne Dzierma, Katrin Manda, et al.
Frontiers in Immunology|October 25, 2023
Immunosuppressive M2 TAMs represent a promising target population to enhance phagocytosis of ovarian cancer cells in vitroFranziska Brauneck, Leticia Oliveira-Ferrer, Jana Muschhammer, et al.
Journal for Immunotherapy of Cancer|December 22, 2022
TIGIT blockade repolarizes AML-associated TIGIT+ M2 macrophages to an M1 phenotype and increases CD47-mediated phagocytosisFranziska Brauneck, Brit Fischer, Marius Witt, et al.
Journal of Leukocyte Biology|February 15, 2017
Down-regulation of CD73 on B cells of patients with viremic HIV correlates with B cell activation and disease progressionEun-Seong Kim, Christin Ackermann, Ilona Tóth, et al.
The Journal of Infectious Diseases|September 25, 2018
Detection of a Broad Range of Low-Level Major Histocompatibility Complex Class II-Restricted, Hepatitis Delta Virus (HDV)-Specific T-Cell Responses Regardless of Clinical StatusJohanna Landahl, Jan Hendrik Bockmann, Christoph Scheurich, et al.
Pageof 2